Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study

Author:

Mian HiraORCID,Seow HsienORCID,Pond Gregory R.ORCID,Gayowsky Anastasia,Foley RonanORCID,Balistky Amaris,Ebraheem Mohammed,Cipkar Christopher,Sapru Hyra,Mohyuddin Ghulam Rehman,Hadidi Samer AlORCID,Visram Alissa

Publisher

Elsevier BV

Reference30 articles.

1. Lyon, France: IARC Press; 2008. WHO classification of tumours of haematopoietic and lymphoid tissues;Swerdlow,2008

2. How I treat triple-class refractory multiple myeloma;Costa;Br J Haematol,2022

3. Immunotherapy for the treatment of multiple myeloma;Boussi;Front Immunol,2022

4. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma;Zanwar;Leukemia,2022

5. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies;Bal;Leukemia,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3